Anti-HIV lectins and current delivery strategies
Lectins, a class of carbohydrate binding agents (CBAs), have been widely studied for their potential antiviral activity. In general, lectins exert their anti-HIV microbicidal activity by binding to viral envelope glycoproteins which hinders a proper interaction between the virus and its host, thereb...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AIMS Press
2018-03-01
|
| Series: | AIMS Molecular Science |
| Subjects: | |
| Online Access: | http://www.aimspress.com/Molecular/article/1911/fulltext.html |
| _version_ | 1818174426885128192 |
|---|---|
| author | Fohona S. Coulibaly Danielle N. Thomas Bi-Botti C. Youan |
| author_facet | Fohona S. Coulibaly Danielle N. Thomas Bi-Botti C. Youan |
| author_sort | Fohona S. Coulibaly |
| collection | DOAJ |
| description | Lectins, a class of carbohydrate binding agents (CBAs), have been widely studied for their potential antiviral activity. In general, lectins exert their anti-HIV microbicidal activity by binding to viral envelope glycoproteins which hinders a proper interaction between the virus and its host, thereby preventing viral entry and replication processes. Several natural lectins extracted from plant, fungi, algae, bacteria and animals, as well as boronic acid-based synthetic lectins, have been investigated against the Human Immunodeficiency Virus (HIV). This manuscript discusses the nature of HIV envelope glycoprotein glycans and their implication in lectin antiviral activity for HIV/AIDS prevention. In addition, anti-HIV lectins and their carbohydrate specificity is reported. Furthermore, current formulations of anti-HIV lectins are presented to illustrate how to overcome delivery challenges. Although antiviral lectins will continue to occupy a major stage in future microbicide research, further investigation in this field should focus on novel delivery strategies and the clinical translation of CBAs. |
| first_indexed | 2024-12-11T19:44:13Z |
| format | Article |
| id | doaj.art-9cc2a17a0a1c46bcbd87d85305e33c03 |
| institution | Directory Open Access Journal |
| issn | 2372-0301 |
| language | English |
| last_indexed | 2024-12-11T19:44:13Z |
| publishDate | 2018-03-01 |
| publisher | AIMS Press |
| record_format | Article |
| series | AIMS Molecular Science |
| spelling | doaj.art-9cc2a17a0a1c46bcbd87d85305e33c032022-12-22T00:52:57ZengAIMS PressAIMS Molecular Science2372-03012018-03-01519611610.3934/molsci.2018.1.96molsci-05-01-096Anti-HIV lectins and current delivery strategiesFohona S. Coulibaly0Danielle N. Thomas1Bi-Botti C. Youan2Laboratory of Future Nanomedicines and Theoretical Chronopharmaceutics, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri Kansas City, USALaboratory of Future Nanomedicines and Theoretical Chronopharmaceutics, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri Kansas City, USALaboratory of Future Nanomedicines and Theoretical Chronopharmaceutics, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri Kansas City, USALectins, a class of carbohydrate binding agents (CBAs), have been widely studied for their potential antiviral activity. In general, lectins exert their anti-HIV microbicidal activity by binding to viral envelope glycoproteins which hinders a proper interaction between the virus and its host, thereby preventing viral entry and replication processes. Several natural lectins extracted from plant, fungi, algae, bacteria and animals, as well as boronic acid-based synthetic lectins, have been investigated against the Human Immunodeficiency Virus (HIV). This manuscript discusses the nature of HIV envelope glycoprotein glycans and their implication in lectin antiviral activity for HIV/AIDS prevention. In addition, anti-HIV lectins and their carbohydrate specificity is reported. Furthermore, current formulations of anti-HIV lectins are presented to illustrate how to overcome delivery challenges. Although antiviral lectins will continue to occupy a major stage in future microbicide research, further investigation in this field should focus on novel delivery strategies and the clinical translation of CBAs.http://www.aimspress.com/Molecular/article/1911/fulltext.htmlanti-HIV lectinssynthetic lectinsHIV gp120HIV gp41glycansdrug delivery |
| spellingShingle | Fohona S. Coulibaly Danielle N. Thomas Bi-Botti C. Youan Anti-HIV lectins and current delivery strategies AIMS Molecular Science anti-HIV lectins synthetic lectins HIV gp120 HIV gp41 glycans drug delivery |
| title | Anti-HIV lectins and current delivery strategies |
| title_full | Anti-HIV lectins and current delivery strategies |
| title_fullStr | Anti-HIV lectins and current delivery strategies |
| title_full_unstemmed | Anti-HIV lectins and current delivery strategies |
| title_short | Anti-HIV lectins and current delivery strategies |
| title_sort | anti hiv lectins and current delivery strategies |
| topic | anti-HIV lectins synthetic lectins HIV gp120 HIV gp41 glycans drug delivery |
| url | http://www.aimspress.com/Molecular/article/1911/fulltext.html |
| work_keys_str_mv | AT fohonascoulibaly antihivlectinsandcurrentdeliverystrategies AT daniellenthomas antihivlectinsandcurrentdeliverystrategies AT bibotticyouan antihivlectinsandcurrentdeliverystrategies |